WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) will present preclinical data on its experimental breast cancer drug candidate at the American Association for Cancer Research Annual Meeting 2026, the company announced.
The poster presentation will feature data on PRT13722, an oral KAT6A selective degrader being developed for estrogen receptor-positive breast cancer.
The AACR Annual Meeting is scheduled for April 17-22, with Prelude’s poster session set for April 21 from 2:00 p.m. to 5:00 p.m. in Poster Section 15.
“We look forward to sharing additional preclinical data from our … KAT6A degrader development candidate, PRT13722,” said Peggy Scherle, chief scientific officer at Prelude. She added that the company expects to file an investigational new drug application in mid-2026 and begin clinical trials in the second half of the year.
According to the company, PRT13722 is designed to selectively degrade the KAT6A protein, a target associated with certain breast cancers, with the goal of improving treatment effectiveness and tolerability compared to existing approaches.
Prelude said it previously presented initial preclinical findings on the program at the AACR Annual Meeting 2025.
In addition to the poster presentation, Norman Fultang, the company’s director of biology and translational research, is scheduled to speak April 18 during an educational session focused on targeted therapies.
Prelude Therapeutics develops experimental cancer treatments, including programs targeting KAT6A and JAK2 mutations.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.